Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDR-END Plus in Rifampicin-Resistant Tuberculosis
NCT07675954Phase 3Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2026
- Primary completion
- Jun 2032
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of delpazolid in Tuberculosis (TB) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Favourable treatment outcome and Composite safety and tolerability endpoint. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
delpazolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07675954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675954.